Abzena

The company's history began with the founding of PolyTherics in 2001 by Professor Steve Brocchini and Dr. Sunil Shaunak, which emerged from research at the University College London and Imperial College London. Abzena itself was formally established in 2013 through the merger of PolyTherics and Antitope. This was followed by a series of strategic acquisitions to broaden its capabilities, including PacificGMP in 2015 for biopharmaceutical manufacturing and The Chemistry Research Solution (TCRS) in 2016 to enhance its ADC services. The company went public with an IPO on the London Stock Exchange in 2014, raising £20 million. In 2018, Abzena was acquired by the private equity firm Welsh, Carson, Anderson & Stowe (WCAS) in a take-private deal, which has since made significant investments to expand its facilities and capacity.

Abzena's business model is twofold: it generates revenue through its fee-for-service contract research and manufacturing operations and also through potential future income from licensing its proprietary technologies. This includes its ThioBridge® platform for creating more stable and effective ADCs and its Composite Human Antibody™ platform for reducing immunogenicity. The company serves a global client base ranging from emerging biotech startups to large pharmaceutical companies. Its services cover antibody discovery, protein engineering, cell line development, process and analytical development, and cGMP manufacturing. Abzena operates facilities in San Diego, California; Bristol, Pennsylvania; and Cambridge, UK.